

Usefulness of *stx2* subtyping as an extension to ISO/TS 13136:2012 for detection of STEC

Louisa Obari^{1,3}, Flemming Scheutz², Søren Aabo¹ & Marianne Sandberg³

¹Technical University of Denmark (DTU), ²Statens Serum Institut (SSI), ³Danish Agriculture & Food Council.

Background

The work was initiated because the EU Commission was about to suggest a guidance on how to manage Shiga-toxin-producing *Escherichia coli* (STEC) findings in food, not including the most updated knowledge of *stx2* subtyping. The suggested ISO/TS 13136:2012 (ISO) method is long-lasting, and would in the first steps (which take 4-5 days), produce many false positive samples. Implementation of the guidance could hence be a practical, and economical challenge for the abattoirs and food processing industry as well, as at the retail level.

A review of the scientific literature indicated that presence of *stx2a* is the most significant disease marker. But *stx2d* has also been associated with Hemolytic uremic syndrome (HUS). *Stx2a* and *stx2c* are the most common subtypes in STEC O157, and have therefore been the main focus in our study.

Hence an extra PCR-step in the ISO method which can determine the *stx* subtypes - samples harbouring hazard genes will be identified at day one - and the further culturing and characterization of the disease properties of the bacteria, would be more targeted and faster.

Aim

Our aim is to investigate whether a nested PCR, including a step with *stx2* subtyping as an extension of the ISO method, performed better than the original ISO method. First step was to investigate the performance of primers and polymerase in regard to ability to detect *stx2* subtypes *stx2a*, *b*, *c*, *d*, *f* and *g* in STEC O157.

Materials & Methods

Protocol: <http://www.ssi.dk/~media/Indhold/EN%20%20engelsk/Public%20Health/National%20Reference%20Laboratories/vtx%20detection%20%20subtyping%20protocolrev6final.ashx> was used to analyze 16 STEC isolates O157 (8 from human and 8 from cattle), from which *stx2c* previously was isolated by Rolgaard et al. 2004

Discussion

What seemed to be *stx2a* in the samples using polymerase GE Healthcare, Illustra puReTaq Ready-To-Go PCR Beads might well be *stx2c* as the position of *stx2a* and *stx2c* is very close to each other.

Because the *stx2a* band was weak, it demanded further investigation and verification. Statens Serum Institut conducted hence an analysis using polymerase HotStarTaq, Qiagen that only gave a *stx2c* as result. This result could indicate that not all polymerase can be used. A second verification will be conducted.

Acknowledgement: I am grateful to, G. Ficher DTU, T. Buschhardt DTU and S. Jespersen SSI for help and guidance.

Results

Results from the 16 STEC O157 tested for the presence of *stx2a* and *c* subtypes are shown in figure a-c. Figure d shows control strains, as described by Scheutz et al. 2012

a




Figure a shows a gel picture of the presence of *stx2c* positive strains in the samples. The *stx2c* Bands ought to lie near 177 base pair (bp). The gel picture clearly illustrates that 14 samples had Bands near 177 bp and two were negative (human isolates samples.)

b




Figure b illustrates what seemed to be *stx2a*. The bands present were, however, very weak and localized around 349 bp, near the band for the positive controls. The negative control remained negative.

c




Figure c shows the results from analyses conducted at SSI. The STEC isolates were tested for *stx2a*, *b*, *c* and *d*, but only *stx2c* was present.

d




Figure d shows a gel picture of the positive controls – conducted to make sure they were stable.

References

- Delannoy S, Mariani-Kurkdjian P, Bonacorsi S, Liguori S, Fach P. Characteristics of Emerging Human-Pathogenic *Escherichia coli* O26:H11 Strains Isolated in France between 2010 and 2013 and Carrying the *stx*_{2d} Gene Only. Ledebøer NA, ed. *Journal of Clinical Microbiology*. 2015;53(2):486-492. doi:10.1128/JCM.02290-14.
- Brandal LT, Wester AL, Lange H, et al. Shiga toxin-producing *Escherichia coli* infections in Norway, 1992–2012: characterization of isolates and identification of risk factors for haemolytic uremic syndrome. *BMC Infectious Diseases*. 2015;15:324. doi:10.1186/s12879-015-1017-6.
- K. VERSTRAETE, K. DE REU, S. VAN WEYENBERG, D. PIÉRARD, L. DE ZUTTER, L. HERMAN, J. ROBYN and M. HEYNDRICKX (2013). Genetic characteristics of Shiga toxin-producing *E. coli* O157, O26, O103, O111 and O145 isolates from humans, food, and cattle in Belgium. *Epidemiology and Infection*, 141, pp 2503-2515. doi:10.1017/S0950268813000307.
- Bielaszewska M, Mellmann A, Bletz S, Zhang W, Kock R, Kossow A, Prager R, Fruth A, Orth-Holler D, Marejkova M, Morabito S, Caprioli A, Pierard D, Smith G, Jenkins C, Curova K, Karch H 2013. Enterohemorrhagic *Escherichia coli* O26:H11/H–: a new virulent clone emerges in Europe. *Clin Infect Dis* 56:1373–1381. doi:.10.1093/cid/cit055
- Scheutz F, Møller Nielsen E, Frimodt-Møller J, Boisen N, Morabito S, Tozzoli R, Nataro JP, Caprioli A. Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing *Escherichia coli* O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. *Euro Surveill*. 2011;16(24):pii=19889
- Zweifel C, Cernela N, Stephan R. Detection of the Emerging Shiga Toxin-Producing *Escherichia coli* O26:H11/H– Sequence Type 29 (ST29) Clone in Human Patients and Healthy Cattle in Switzerland. *Applied and Environmental Microbiology*. 2013;79(17):5411-5413. doi:10.1128/AEM.01728-13.
- Byrne L, Vanstone GL, Perry NT, Lauenders N, Adak GK, Godbole G, et al. Epidemiology and microbiology of Shiga toxin-producing *Escherichia coli* other than serogroup O157 in England, 2009-2013. *J Med Microbiol*. 2014;63(Pt 9):1181-8. <http://dx.doi.org/10.1099/jmm.0.075895-0> PMID:24928216
- Scheutz F, Teel LD, Beutin L, et al. Multicenter Evaluation of a Sequence-Based Protocol for Subtyping Shiga Toxins and Standardizing Stx Nomenclature. *Journal of Clinical Microbiology*. 2012;50(9):2951-2963. doi:10.1128/JCM.00860-12.
- Boisen N, Melton-Celsa AR, Scheutz F, O'Brien AD, Nataro JP, et al. Shiga toxin 2a and Enteroaggregative *Escherichia coli* - a deadly combination 2015 Jul 4;6(4):272-8. doi: 10.1080/19490976.2015.1054591. Epub 2015 Jun 3
- Marejková M, Bláhová K, Janda J, Fruth A, Petráš P. Enterohemorrhagic *Escherichia coli* as Causes of Hemolytic Uremic Syndrome in the Czech Republic. Yam W-C, ed. *PLoS ONE*. 2013;8(9):e73927. doi:10.1371/journal.pone.0073927.
- Konno T, Yatsuyanagi J, Takahashi S, Kumagai Y, Wada E, Chiba M, Saito S, et al. Determination of Enterohemorrhagic *Escherichia coli* Serotype O165:HNM Infection in a Hemolytic Uremic Syndrome Patient with Adenovirus Serotype 41 2013;66(5):394-7. <http://doi.org/10.7883/yoken.66.394>
- Haugum K, Johansen J, Gabrielsen C, et al. Comparative Genomics to Delineate Pathogenic Potential in Non-O157 Shiga Toxin-Producing *Escherichia coli* (STEC) from Patients with and without Haemolytic Uremic Syndrome (HUS) in Norway. Rodrigues MM, ed. *PLoS ONE*. 2014;9(10):e111788. doi:10.1371/journal.pone.0111788.
- Fuller CA, Pellino CA, Flagler MJ, Strasser JE, Weiss AA. Shiga Toxin Subtypes Display Dramatic Differences in Potency . *Infection and Immunity*. 2011;79(3):1329-1337. doi:10.1128/IAI.01182-10.
- Kameyama M, Yabata J, Nomura Y, Tominaga K, et al. Biochemical Features and Virulence Gene Profiles of Non-O157/O26 Enterohemorrhagic *Escherichia coli* Strains from Humans in the Yamaguchi Prefecture, Japan. 2015;68(3):216-20. doi: 10.7883/yoken.JJID.2014.303. Epub 2015 Jan 20.
- Kunsmann L, Rüter C, Bauwens A, et al. Virulence from vesicles: Novel mechanisms of host cell injury by *Escherichia coli* O104:H4 outbreak strain. *Scientific Reports*. 2015;5:13252. doi:10.1038/srep13252.
- Beutin L, Hammerl JA, Reetz J, Strauch E.. Shiga toxin-producing *Escherichia coli* strains from cattle as a source of the Stx2a bacteriophages present in enteroaggregative *Escherichia coli* O104:H4 strains. *Int J Med Microbiol* (2013) 303:595–602.10.1016/j.ijmm.2013.08.001
- European Centre for Disease Prevention and Control and European Food Safety Authority. Shiga toxin/verotoxin-producing *Escherichia coli* in humans, food and animals in the EU/EEA, with special reference to the German outbreak strain STEC O104. Stockholm: ECDC; 2011.
- EFSA Panel on Biological Hazards (BIOHAZ); Scientific Opinion on VTEC-seropathotype and scientific criteria regarding pathogenicity assessment. *EFSA Journal* 2013;11(4):3138. [106 pp.] doi:10.2903/j.efsa.2013.3138. Available online: www.efsa.europa.eu/efsajournal
- Dallman T, Ashton P, Byrne L, Perry N, Petrovska L, Ellis R, Allison L, Hanson M, Holmes A, Gunn G, Chase-Topping M, Woolhouse M, Grant K, Gally D, Wain J, Jenkins C. Applying phylogenomics to understand the emergence of Shiga-toxin-producing *Escherichia coli* O157:H7 strains causing severe human disease in the UK 14/09/2015. *M Gen* 1(3): doi:10.1099/mgen.0.000029
- Roldgaard, BB, Scheutz, F, Boel, J, Aabo, S, Schultz, AC, Cheasty, T, Nielsen, EM, Olsen, KEP & Christensen, BB 2004, 'VTEC O157 subtypes associated with the most severe clinical symptoms in humans constitute a minor part of VTEC O157 isolates from Danish Cattle' *International Journal of Medical Microbiology*, vol 294, no. 4, pp. 255-259.